In our retrospective study, ILC was compared with NST based on pooled data from the three large prospective adjuvant breast cancer trials, SUCCESS A, B, and C, where intermediate-to-high-risk patients were treated with chemotherapy as well as endocrine and/or HER2-targeted therapy, depending on HR status and HER2neu status. Here, ERBB2 is linked to breast cancer.